IMF releases lacklustre results, but that's not the whole story

2014 and 2015 looking strong for litigation funder.

a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

IMF (ASX: IMF) has announced 2013 results, highlights include:

  • Net income from cases down 66%
  • Net profit after tax down 68% to $13.8m
  • Annual dividend halved to 5c (ff)
  • Earnings per share down 68%
  • Net asset backing up 12% to $1.02
  • Value of investment portfolio up 33% to $1.63b
  • Cash up 12% to $70m

Superficially, a poor result. Or is it?

Litigation funders such as IMF are best seen as portfolio managers, with the investments being court cases. Earnings vary considerably year to year, as cases are finalised or extended. On average, it takes two to three years for a class action to finalise.

In their presentation, IMF expects possible completions of $765 million in 2014 and $740 million in 2015. Potential income (not profit) from these expectations is $130 million in 2014 and $126 million in 2015. Net after tax profit as a percentage of income averages 30%; so potential profits of $39 million and $38 million are in play. No allowance is made for any new cases.

Meanwhile, US subsidiary Bentham Capital is gaining positive traction and expansion into the UK is being considered. Due diligence into possible actions against rating agencies and related parties is well advanced and it looks very likely significant actions will be commenced.

Investors have welcomed the report, sending the share price up to $2.04. In this Fool's view, this confidence is not misplaced and IMF is a solid long-term buy.

Interested in our #1 dividend-paying stock? Discover The Motley Fool's favourite income idea for 2013-2014 in our brand-new, FREE research report, including a full investment analysis! Simply click here for your FREE copy of "The Motley Fool's Top Dividend Stock for 2013-2014."  

More reading


Motley Fool contributor Peter Andersen owns shares in IMF

More on ⏸️ Investing

A white and black robot in the form of a human being stands in front of a green graphic holding a laptop and discussing robotics and automation ASX shares
Technology Shares

Joining the revolution: How I'd invest in ASX AI shares right now

Advances in artificial intelligence (AI) could usher in a new industrial revolution. Here’s how you can invest in it.

Read more »

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »